Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location Micah.

Slides:

Advertisements

Similar presentations

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Advertisements

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Are good patient and embryo characteristics protective against the negative effect of elevated progesterone level on the day of oocyte maturation? Micah.

A giant oocyte in a cohort of retrieved oocytes: does it have any effect on the in vitro fertilization cycle outcome? Ronit Machtinger, M.D., Joseph.

Nicole Banks, M. D. , George Patounakis, M. D. , Ph. D

Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger? Matthew.

Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation.

Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology.

Ectopic pregnancy diagnosis and the pseudo-sac

Mike Ripley, M. D. , F. R. C. S. C. , Andrea Lanes, M. Sc

Idiopathic liver function test abnormality in pregnancy is associated with assisted reproduction techniques Uri Kopylov, M.D., Benjamin Avidan, M.D.,

Trophectoderm grade predicts outcomes of single-blastocyst transfers

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Dramatic declines in implantation and pregnancy rates in patients who undergo repeated cycles of in vitro fertilization with blastocyst transfer after.

A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization.

Appraisal of clinical complications after 23,827 oocyte retrievals in a large assisted reproductive technology program Paolo Emanuele Levi-Setti, M.D.,

Orhan Bukulmez, M. D. , Qin Li, M. S. , Bruce R. Carr, M. D

Genotypically determined ancestry across an infertile population: ovarian reserve and response parameters are not influenced by continental origin Meir.

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss.

Two interesting cases of ovarian pregnancy after in vitro fertilization–embryo transfer and its successful laparoscopic management Selvaraj Priya, M.D.,

Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response Frank.

Progesterone luteal support after ovulation induction and intrauterine insemination: a systematic review and meta-analysis Micah J. Hill, D.O., Brian.

Matthew T. Connell, D. O. , Jennifer M. Szatkowski, B. S

Influences on endometrial development during intrauterine insemination: clinical experience of 2,929 patients with unexplained infertility Erin Foran.

Lisa Marii Cookingham, M. D. , Rachel P. Goossen, B. A. , Amy E. T

Albert Hsu, M. D. , Margaret Arny, Ph. D. , Alexander B. Knee, M. S

Common 677C→T mutation of the 5,10-methylenetetrahydrofolate reductase gene affects follicular estradiol synthesis Stephanie Hecht, Roman Pavlik, Peter.

Prospective study into the value of the automated Elecsys antimüllerian hormone assay for the assessment of the ovarian growing follicle pool Richard.

Microdose flare protocol with interrupted follicle stimulating hormone and added androgen for poor responders—an observational pilot study Frederic Mitri,

Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study Li Wei, Ph.D., Thomas MacDonald, M.D.,

Effect of Salpingectomy on Ovarian Reserve: A Systematic Review and Meta-Analysis C.E. Boots, MD, E.A. Seidler, MD, A. Ainsworth, MD, A. Hardi, MLIS,

A new approach to ovarian reserve testing

Revisiting the progesterone to oocyte ratio

The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis

David E. Reichman, M.D., Dan Goldschlag, M.D., Zev Rosenwaks, M.D.

Are intracytoplasmic sperm injection and high serum estradiol compounding risk factors for adverse obstetric outcomes in assisted reproductive technology?

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

From partner's desk to iPad

Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Reshef Tal,

Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis.

Does a frozen embryo transfer ameliorate the effect of elevated progesterone seen in fresh transfer cycles? Mae Wu Healy, D.O., George Patounakis, M.D.,

Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized.

Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis Katherine A. Green,

Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.

Stephanie L. F. Gustin, M. D. , Gourab Mukherjee, Valerie L. Baker, M

Diminished intrafollicular estradiol levels in in vitro fertilization cycles from women with reduced ovarian response to recombinant human follicle-stimulating.

Melatonin supplementation during controlled ovarian stimulation for women undergoing assisted reproductive technology: systematic review and meta-analysis.

Tolga B. Mesen, M. D. , Lamya Kacemi-Bourhim, M. D. , Paul B

Orhan Bukulmez, M. D. , Bruce R. Carr, M. D. , Kathleen M. Doody, M. D

Efficacy and safety of human chorionic gonadotropin for follicular phase stimulation in assisted reproduction: a systematic review and meta-analysis

Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities.

Efficacy of intrauterine inseminations as a training modality for performing embryo transfer in reproductive endocrinology and infertility fellowship.

Aviad Cohen, M. D. , Guy Bibi, M. D. , Benny Almog, M. D

Bruce S Shapiro, M. D. , Kevin S Richter, Ph. D. , Dee C Harris, M. T

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Stephanie A. Beall, M.D., Ph.D., Alan DeCherney, M.D.

Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis.

Circulating microRNAs as potential biomarkers for endometriosis

James M. Hotaling, M. D. , M. S. , Natalya A. Lopushnyan, M. D

Eric S. Surrey, M. D. , Debra A. Minjarez, M. D. , John M. Stevens, B

Thin endometrial stripe does not affect likelihood of achieving pregnancy in clomiphene citrate/intrauterine insemination cycles Albert Asante, M.D.,

David H. Barad, M.D., M.S., Norbert Gleicher, M.D.

Experience with a patient-friendly, mandatory, single-blastocyst transfer policy: the power of one John M. Csokmay, M.D., Micah J. Hill, D.O., Rebecca.

Bárbara Oriol, M. D. , Ana Barrio, M. D. , Alberto Pacheco, Ph. D

Effect of methotrexate exposure on subsequent fertility in women undergoing controlled ovarian stimulation Janet F. McLaren, M.D., Richard O. Burney,

Conversion from assisted reproductive technology to intrauterine insemination in low responders: Is it advantageous? John M. Norian, M.D., Eric D. Levens,

The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review.

Presentation transcript:

Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location Micah J. Hill, D.O., Janelle C. Cooper, M.D., Gary Levy, M.D., Connie Alford, M.D., Kevin S. Richter, Ph.D., Alan H. DeCherney, M.D., Charles L. Katz, M.D., Eric D. Levens, M.D., Erin F. Wolff, M.D. Fertility and Sterility Volume 101, Issue 2, Pages 413-419.e4 (February 2014) DOI: 10.1016/j.fertnstert.2013.10.027 Copyright © 2014 Terms and Conditions

Figure 1 Box and whisker plots of pretreatment and posttreatment oocyte yield, AFC, and FSH values in the surgical and methotrexate groups. Boxes represent the interquartile range, and the line within the boxes represent the median. The vertical lines protruding from the box extend to the minimum and the maximum values of the data set so long as these values do not differ from the median by more than 1.5 times the interquartile range. Outliers from this range are represented by dots. There were no statistically significant differences between pretreatment and posttreatment values within either group. Fertility and Sterility 2014 101, 413-419.e4DOI: (10.1016/j.fertnstert.2013.10.027) Copyright © 2014 Terms and Conditions

Figure 2 Scatterplots of the change in oocyte yield from pretreatment to posttreatment values plotted against the time between ART cycles in day. (A) Includes all patients in the methotrexate group out to 1,780 days. (B) Includes only patients in the methotrexate group having a repeat ART cycle with 365 days. Fertility and Sterility 2014 101, 413-419.e4DOI: (10.1016/j.fertnstert.2013.10.027) Copyright © 2014 Terms and Conditions

Supplemental Figure 1 Less than efficiency curve evaluating time between ART cycles and the change in oocyte yield from pretreatment to posttreatment values. The change in oocyte yield was calculated for all values below each time point in increments of 25 days. Patients with <100 days between cycles had an oocyte yield change of +2.8; however, that group consisted of only five patients. Otherwise, there was no postmethotrexate time effect on oocyte yield. Fertility and Sterility 2014 101, 413-419.e4DOI: (10.1016/j.fertnstert.2013.10.027) Copyright © 2014 Terms and Conditions

Supplemental Figure 2 Scatterplots of the change in AFC yield from pretreatment to posttreatment values plotted against the time between ART cycles in day. (A) Includes all patients in the methotrexate group out to 1,780 days. (B) Includes only patients in the methotrexate group having a repeat ART cycle with 365 days. Fertility and Sterility 2014 101, 413-419.e4DOI: (10.1016/j.fertnstert.2013.10.027) Copyright © 2014 Terms and Conditions

Supplemental Figure 3 Scatterplots of the change in FSH yield from pretreatment to posttreatment values plotted against the time between ART cycles in days. Patients undergoing repeat ART cycle within 1 year typically did not have repeat FSH testing performed. Fertility and Sterility 2014 101, 413-419.e4DOI: (10.1016/j.fertnstert.2013.10.027) Copyright © 2014 Terms and Conditions